These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18568884)

  • 1. Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert.
    Mundada AS; Shrikhande BK
    Curr Eye Res; 2008 May; 33(5):469-75. PubMed ID: 18568884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride.
    Mundada AS; Shrikhande BK
    Drug Dev Ind Pharm; 2006 Apr; 32(4):443-8. PubMed ID: 16638682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged delivery of ciprofloxacin hydrochloride from hydrophilic ocular inserts.
    Samanta A; Ghosal SK
    Acta Pol Pharm; 2004; 61(5):343-9. PubMed ID: 15747690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly[LA-(Glc-Leu)] copolymer as a carrier for ocular delivery of ciprofloxacin: formulation, characterization and in vivo biocompatibility study.
    Pagar KP; Vavia PR
    Ther Deliv; 2013 May; 4(5):553-65. PubMed ID: 23647274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycerogelatin-based ocular inserts of aceclofenac: physicochemical, drug release studies and efficacy against prostaglandin E₂-induced ocular inflammation.
    Mathurm M; Gilhotra RM
    Drug Deliv; 2011 Jan; 18(1):54-64. PubMed ID: 20718601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: in vitro and in vivo studies.
    Charoo NA; Kohli K; Ali A; Anwer A
    Drug Dev Ind Pharm; 2003 Feb; 29(2):215-21. PubMed ID: 12648018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and evaluation of ocular drug delivery system for controlled delivery of gatifloxacin sesquehydrate: In vitro and in vivo evaluation.
    Patel UL; Chotai NP; Nagda CD
    Pharm Dev Technol; 2012; 17(1):15-22. PubMed ID: 20649410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hydroxypropyl-beta-cyclodextrin on the solubility, stability and in-vitro release of ciprofloxacin for ocular drug delivery.
    Bozkir A; Denli ZF; Basaran B
    Acta Pol Pharm; 2012; 69(4):719-24. PubMed ID: 22876616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular bioavailability of ciprofloxacin in sustained release formulations.
    Ke TL; Cagle G; Schlech B; Lorenzetti OJ; Mattern J
    J Ocul Pharmacol Ther; 2001 Dec; 17(6):555-63. PubMed ID: 11777179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of mucoadhesive nanosuspension of ciprofloxacin.
    Jain V; Kare P; Jain D; Singh R
    Acta Pol Pharm; 2011; 68(2):273-8. PubMed ID: 21485301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and evaluation of controlled release antibiotic biodegradable implants for post operative site delivery.
    Mathur V; Mudnaik R; Barde L; Roy A; Shivhare U; Bhusari K
    Acta Pharm; 2010 Mar; 60(1):111-7. PubMed ID: 20228045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thermosensitive and pH induced in situ ophthalmic gelling system for ciprofloxacin hydrochloride: hydroxypropyl-beta-cyclodextrin complex.
    Başaran B; Bozkir A
    Acta Pol Pharm; 2012; 69(6):1137-47. PubMed ID: 23285675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation.
    Ong HX; Benaouda F; Traini D; Cipolla D; Gonda I; Bebawy M; Forbes B; Young PM
    Eur J Pharm Biopharm; 2014 Jan; 86(1):83-9. PubMed ID: 23851077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antiinfectious biomaterials. Ciprofloxacin containing polyurethanes as potential drug delivery systems to prevent foreign-body infections.
    Schierholz JM; Rump A; Pulverer G
    Arzneimittelforschung; 1997 Jan; 47(1):70-4. PubMed ID: 9037447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and evaluation of moxifloxacin hydrochloride ocular inserts.
    Pawar PK; Katara R; Majumdar DK
    Acta Pharm; 2012 Mar; 62(1):93-104. PubMed ID: 22472452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ophthalmic controlled release in situ gelling systems for ciprofloxacin based on polymeric carriers.
    Al-Kassas RS; El-Khatib MM
    Drug Deliv; 2009 Apr; 16(3):145-52. PubMed ID: 19514974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicomposite ultrathin capsules for sustained ocular delivery of ciprofloxacin hydrochloride.
    Bhadra D; Gupta G; Bhadra S; Umamaheshwari RB; Jain N
    J Pharm Pharm Sci; 2004 Jul; 7(2):241-51. PubMed ID: 15367382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment.
    Mehanna MM; Elmaradny HA; Samaha MW
    Drug Dev Ind Pharm; 2010 Jan; 36(1):108-18. PubMed ID: 19656004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular delivery systems of pefloxacin mesylate.
    Bharath S; Hiremath SR
    Pharmazie; 1999 Jan; 54(1):55-8. PubMed ID: 9987797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ ophthalmic gel of ciprofloxacin hydrochloride for once a day sustained delivery.
    Jain SP; Shah SP; Rajadhyaksha NS; Singh P S PP; Amin PD
    Drug Dev Ind Pharm; 2008 Apr; 34(4):445-52. PubMed ID: 18401787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.